U.S. Markets closed
  • S&P 500

    4,432.99
    -40.76 (-0.91%)
     
  • Dow 30

    34,584.88
    -166.42 (-0.48%)
     
  • Nasdaq

    15,043.97
    -137.93 (-0.91%)
     
  • Russell 2000

    2,236.87
    +3.96 (+0.18%)
     
  • Crude Oil

    71.96
    -0.01 (-0.01%)
     
  • Gold

    1,753.90
    +2.50 (+0.14%)
     
  • Silver

    22.42
    +0.13 (+0.58%)
     
  • EUR/USD

    1.1736
    -0.0036 (-0.3051%)
     
  • 10-Yr Bond

    1.3700
    +0.0390 (+2.93%)
     
  • Vix

    20.81
    +2.12 (+11.34%)
     
  • GBP/USD

    1.3747
    -0.0050 (-0.3602%)
     
  • USD/JPY

    109.9110
    +0.1930 (+0.1759%)
     
  • BTC-USD

    47,549.50
    -485.83 (-1.01%)
     
  • CMC Crypto 200

    1,193.48
    -32.05 (-2.61%)
     
  • FTSE 100

    6,963.64
    -63.84 (-0.91%)
     
  • Nikkei 225

    30,500.05
    +176.75 (+0.58%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPCE, OCGN and CRMD

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / July 27, 2021 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Virgin Galactic Holdings, Inc. (NYSE:SPCE)

Investors Affected : October 26, 2019 - April 30, 2021

A class action has commenced on behalf of certain shareholders in Virgin Galactic Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) for accounting purposes, Social Capital Hedosophia Holdings Corp.'s ("SCH") warrants were required to be treated as liabilities rather than equities; (ii) Virgin Galactic had deficient disclosure controls and procedures and internal control over financial reporting; (iii) as a result, the Company improperly accounted for SCH warrants that were outstanding at the time of the business combination; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/virgin-galactic-holdings-inc-loss-submission-form/?id=17999&from=1

Ocugen, Inc. (NASDAQ:OCGN)

Investors Affected : February 2, 2021 - June 10, 2021

A class action has commenced on behalf of certain shareholders in Ocugen, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://securitiesclasslaw.com/securities/ocugen-inc-loss-submission-form/?id=17999&from=1

CorMedix Inc. (NASDAQ:CRMD)

Investors Affected : July 8, 2020 - May 13, 2021

A class action has commenced on behalf of certain shareholders in CorMedix Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/cormedix-inc-loss-submission-form/?id=17999&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/657207/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-SPCE-OCGN-and-CRMD